

# Peptide And Oligonucleotide CDMO Market Analysis With Opportunity Segments For 2024-2033

The Business Research Company's Peptide And Oligonucleotide CDMO Global Market Report 2024 – Market Size, Trends. And Global Forecast 2024-2033

LANDON, GREATER LANDON, UK, July 30, 2024 /EINPresswire.com/ -- The peptide and oligonucleotide CDMO market has experienced robust growth in recent years, expanding from \$1.93 billion in 2023 to \$2.16 billion in 2024



at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to a rise in demand for therapeutic agents, advancements in synthesis and manufacturing, personalized medicine trends, regulatory guidelines, and increased focus on antiviral peptides and mRNA vaccines highlighting the potential of oligonucleotides in vaccine development.



You Can Now Pre Order
Your Report To Get A Swift
Deliver With All Your Needs"
The Business Research
Company

Strong Future Growth Anticipated
The peptide and oligonucleotide CDMO market is
projected to continue its strong growth, reaching \$3.39
billion in 2028 at a compound annual growth rate (CAGR)
of 12.0%. The growth in the forecast period can be
attributed to the growing demand for personalized

medicine, advancements in biotechnology, expanding applications, increasing outsourcing, and the growing burden of chronic diseases.

Explore Comprehensive Insights Into The Global Peptide And Oligonucleotide CDMO Market With A Detailed Sample Report:

https://www.thebusinessresearchcompany.com/sample\_request?id=15892&type=smp

Growth Driver Of The Peptide And Oligonucleotide CDMO Market
The growing adoption of personalized medicine is expected to propel the growth of the peptide

and oligonucleotide CDMO markets going forward. Personalized medicine is an approach to healthcare that tailors medical decisions and treatments to individual characteristics, such as genetics, environment, and lifestyle. The growing adoption of personalized medicine is due to several factors such as advancements in genomic technologies, increased understanding of disease mechanisms at the molecular level, and the demand for more effective and targeted treatment options tailored to individual patients' genetic profiles and medical histories. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) play a crucial role in personalized medicine by producing customized therapeutic peptides and oligonucleotides tailored to individual patient needs.

Explore The Report Store To Make A Direct Purchase Of The Report: <a href="https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmoglobal-market-report">https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmoglobal-market-report</a>

#### Major Players And Market Trends

Key players in the peptide and oligonucleotide CDMO market include Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd.

Major companies operating in the peptide and oligonucleotide CDMO market are focusing on developing strategic partnerships to enhance their service offerings, expand their technological capabilities, and increase their market reach. Peptide development and production partnerships refer to collaborative agreements between two organizations focused on developing and manufacturing peptide-based therapeutics.

#### Segments:

- 1) By Product: Peptides, Oligonucleotides
- 2) By Service Type: Contract Development, Contract Manufacturing,
- 3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications
- 4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Others End Users

Geographical Insights: North America Leading The Market

North America was the largest region in the peptide and oligonucleotide CDMO market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

## Peptide And Oligonucleotide CDMO Market Definition

A peptide and oligonucleotide CDMO (contract development and manufacturing organization) refers to a company that provides services for the development, manufacturing, and supply of peptides and oligonucleotide-based therapeutics. These organizations offer expertise in synthetic chemistry, process development, analytical testing, and cGMP manufacturing to

support the production of peptides and oligonucleotides for various companies.

Peptide And Oligonucleotide CDMO Global Market Report 2024 from The Business Research Company covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Peptide And Oligonucleotide CDMO Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on peptide and oligonucleotide CDMO market size, peptide and oligonucleotide CDMO market drivers and trends, peptide and oligonucleotide CDMO market major players, peptide and oligonucleotide CDMO competitors' revenues, peptide and oligonucleotide CDMO market positioning, and peptide and oligonucleotide CDMO market growth across geographies. The peptide and oligonucleotide CDMO market report helps you gain in-depth insights into opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:

Cell Penetrating Peptide Global Market Report 2024 <a href="https://www.thebusinessresearchcompany.com/report/cell-penetrating-peptide-global-market-report">https://www.thebusinessresearchcompany.com/report/cell-penetrating-peptide-global-market-report</a>

Peptide Antibiotics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/peptide-antibiotics-global-market-report

Glycopeptide Antibiotics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report

### About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60

geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information
The Business Research Company

Europe: +44 207 1930 708 Asia: +91 8897263534

Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:

Facebook

Χ

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/731485823

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.